UBE2J1 and prostate cancer: We hypothesized that high-grade prostate cancer (PCa) patients, particularly those with Gleason scores of 9–10, who are more prone to develop resistance, would exhibit reduced expression of UBE2J1 compared to patients with low-grade tumors (Gleason scores 6–8) [38].